Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies

Journal of Infectious Diseases

Volumn 202, Issue 10, 2010, Pages 1492-1499

  Quenelle, Debra C ^a   Lampert, Bernhardt ^b   Collins, Deborah J ^a   Rice, Terri L ^a   Painter, George R ^b   Kern, Earl R ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Chimerix Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CARBON 14; CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM INFECTION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENCY; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX ENCEPHALITIS; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES ZOSTER; HUMAN; HUMAN CELL; IN VITRO STUDY; INOCULATION; MORTALITY; MOUSE; NONHUMAN; PLAQUE FORMING CELL; PRIORITY JOURNAL; RADIOACTIVITY; VIRUS REPLICATION; VIRUS TITRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; CYTOSINE; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; MICE; MICE, INBRED BALB C; PHOSPHONIC ACIDS; TISSUE DISTRIBUTION;

EID: 78349234678     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/656717     Document Type: Article

References (46)

1. Kramer AH, Bleck TP. Neurocritical care of patients with central nervous system infections. Curr Infect Dis Rep 2007; 9:308-314.
2. Kramer AH, Bleck TP. Neurocritical care of patients with central nervous system infections. Curr Treat Options Neurol 2008; 10:201-211.
3. Riera-Mestre A, Gubieras L, Martinez-Yelamos S, Cabellos C, Fernandez-Viladrich P. Adult herpes simplex encephalitis: fifteen years' experience. Enferm Infec Microbiol Clin 2009; 27:143-147.
4. Tyler KL. Herpes simplex virus infections of the central nervous system: encephalitis and meningitis, including Mollaret's. Herpes 2004; 11(Suppl 2):57A-64A.
5. Whitley RJ. Herpes simplex encephalitis: adolescents and adults. Antiviral Res 2006; 71:141-148.
6. Markoula S, Giannopoulos S, Pelidou SH, Argyropoulou M, Lagos G, Kyritsis AP. MRI deterioration in herpes simplex encephalitis despite clinical recovery. Neurologist 2009; 15:223-226.
7. Poissy J, Wolff M, Dewilde A, et al. Factors associated with delay to acyclovir administration in 184 patients with herpes simplex virus encephalitis. Clin Microbiol Infect 2009; 15:560-564.
8. Chaudhuri A, Kennedy PG. Diagnosis and treatment of viral encephalitis. Postgrad Med J 2002; 78:575-583.
9. James SH, Kimberlin DW, Whitley RJ. Antiviral therapy for herpesvirus central nervous system infections: neonatal herpes simplex virus infection, herpes simplex encephalitis, and congenital cytomegalovirus infection. Antiviral Res 2009; 83:207-213.
10. Jones CA, Walker KS, Badawi N. Antiviral agents for treatment of herpes simplex virus infection in neonates. Cochrane Database Syst Rev 2009; 3:CD004206.
11. Kesson AM. Management of neonatal herpes simplex virus infection. Paediatr Drugs 2001; 3:81-90.
12. Kimberlin D. Herpes simplex virus, meningitis and encephalitis in neonates. Herpes 2004; 11(Suppl 2):65A-76A.
13. Schloss L, Falk KI, Skoog E, Brytting M, Linde A, Aurelius E. Monitoring of herpes simplex virus DNA types 1 and 2 viral load in cerebrospinal fluid by real-time PCR in patients with herpes simplex encephalitis. J Med Virol 2009; 81:1432-1437.
14. Skoldenberg B, Aurelius E, Hjalmarsson A, et al. Incidence and pathogenesis of clinical relapse after herpes simplex encephalitis in adults. J Neurol 2006; 253:163-170.
15. Whitley R. Diagnosis and treatment of herpes simplex encephalitis. Annu Rev Med 1981; 32:335-340.
16. Whitley RJ. Interim summary of mortality in herpes simplex encephalitis and neonatal herpes simplex virus infections: vidarabine versus acyclovir. J Antimicrob Chemother 1983; 12(Suppl B):105-112.
17. Whitley RJ, Alford CA, Hirsch MS, et al. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med 1986; 314:144-149.
18. Kern ER. Animal models as assay systems for the development of antivirals. In: DeClercq E, Walker RT, eds. Antiviral drug development. New York, NY: Plenum Press, 1988, 149-172.
19. Kern ER. Preclinical evaluation of antiviral agents: in vitro and animal model testing. In: Galasso GJ, Whitley RJ, Merigan TC, eds. Antiviral agents and viral diseases of man New York, NY: Raven Press, 1990.
20. Kern ER, Richards JT, Glasgow LA, Overall JC, Jr, de Miranda P. Optimal treatment of herpes simplex virus encephalitis in mice with oral acyclovir. Am J Med 1982; 73:125-131.
21. Kern ER, Richards JT, Overall JC, Jr. Acyclovir treatment of disseminated herpes simplex virus type 2 infection in weanling mice: alteration of mortality and pathogenesis. Antiviral Res 1986; 6:189-195.
22. Whitley RJ, Soong SJ, Dolin R, Galasso GJ, Ch'ien LT, Alford CA. Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis. National Institute of Allergy and Infectious Diseases collaborative antiviral study. N Engl J Med 1977; 297:289-294.
23. Whitley RJ. Herpes simplex virus infections of the central nervous system. Encephalitis and neonatal herpes. Drugs 1991; 42:406-427.
24. Beadle JR, Hartline C, Aldern KA, et al. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob Agents Chemother 2002; 46:2381-2386.
25. Keith KA, Wan WB, Ciesla SL, Beadle JR, Hostetler KY, Kern ER. Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication in vitro. Antimicrob Agents Chemother 2004; 48:1869-1871.
26. Kern ER. In vitro activity of potential anti-poxvirus agents. Antiviral Res 2003; 57:35-40.
27. Kern ER, Collins DJ, Wan WB, Beadle JR, Hostetler KY, Quenelle DC. Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir. Antimicrob Agents Chemother 2004; 48:3516-3522.
28. Kern ER, Hartline C, Harden E, et al. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob Agents Chemother 2002; 46:991-995.
29. Prichard MN, Quenelle DC, Hartline CB, et al. Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides. Antimicrob Agents Chemother 2009; 53:5251-5258.
30. Williams-Aziz SL, Hartline CB, Harden EA, et al. Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro. Antimicrob Agents Chemother 2005; 49:3724-3733.
31. Bidanset DJ, Beadle JR, Wan WB, Hostetler KY, Kern ER. Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection. J Infect Dis 2004; 190:499-503.
32. Quenelle DC, Collins DJ, Wan WB, Beadle JR, Hostetler KY, Kern ER. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob Agents Chemother 2004; 48:404-412.
33. Buller RM, Owens G, Schriewer J, Melman L, Beadle JR, Hostetler KY. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mouse-pox model. Virology 2004; 318:474-481.
34. Parker S, Touchette E, Oberle C, et al. Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model. Antiviral Res 2008; 77:39-49.
35. Huggins JW, Baker RO, Beadle JR, Hostetler KY. Orally active ether lipid prodrugs of cidofovir for treatment of smallpox. Antiviral Res 2002; 53:A66.
36. Quenelle DC, Prichard MN, Keith KA, et al. Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob Agents Chemother 2007; 51:4118-4124.
37. Bernstein DI, Kappes JC. Enhanced in vitro reactivation of latent herpes simplex virus from neural and peripheral tissues with hexamethylenebisacetamide. Arch Virol 1988; 99:57-65.
38. Kern ER. Animal Models for central nervous system and disseminated infections with herpes simplex virus. In: Zak O, Sande MA, eds. Handbook of animal models of infection. San Diego: Academic Press, 1999.
39. Cundy KC, Bidgood AM, Lynch G, Shaw JP, Griffin L, Lee WA. Pharmacokinetics, bioavailability, metabolism, and tissue distribution of cidofovir (HPMPC) and cyclic HPMPC in rats. Drug Metab Dispos 1996; 24:745-752.
40. Safrin S, Cherrington J, Jaffe HS. Clinical uses of cidofovir. Rev Med Virol 1997; 7:145-156.
41. Andrei G, Fiten P, Goubau P, et al. Dual infection with polyomavirus BK and acyclovir-resistant herpes simplex virus successfully treated with cidofovir in a bone marrow transplant recipient. Transpl Infect Dis 2007; 9:126-131.
42. 14C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake andmetabolism. Mol Pharmacol 2003; 63:678-681.
43. Painter GR, Trost LC, Lampert BM, et al. CMX001. Drugs Future 2008; 33:1-7.
44. Thackray AM, Field HJ. Persistence of infectious herpes simplex virus type 2 in the nervous system in mice after antiviral chemotherapy. Antimicrob Agents Chemother 2000; 44:97-102.
45. Lycke J, Malmestrom C, Stahle L. Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir. Antimicrob Agents Chemother 2003; 47:2438-244141.
46. Quenelle DC, Prichard MN, Hartline CB, et al. Enhanced efficacy using suboptimal concentrations of CMX001 with acyclovir against herpes simplex virus infections in vitro and in mice. Antiviral Res 2010; 86:A65.